SCHEMBL859367

SCHEMBL859367

Cc1ccc2ncc(CSc3nc(C)cc(O)n3)n2c1

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.42
MAPT P10636 1/20 0.42
NPSR1 Q6W5P4 1/20 0.38
RCE1 Q9Y256 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
RXFP1 Q9HBX9 2/20 0.36
KMT2A Q03164 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2C9 P11712 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
ALDH1A1 P00352 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13058898 0.83 KDM4E (0.39) KDM4EMAPTGLAGAANPC1
SCHEMBL845268 0.75 L3MBTL1 (0.40) KDM4EMAPTRCE1GAAALDH1A1
SCHEMBL13066867 0.74 KDM4E (0.43) KDM4EMAPTRCE1GAAKMT2A
Hydrochloric Acid SCHEMBL844618 0.74 L3MBTL1 (0.39) KDM4ERCE1GAAALDH1A1HTT
SCHEMBL844560 0.73 L3MBTL1 (0.39) KDM4EMAPTNPSR1RCE1GAA
SCHEMBL5655359 0.71 CYP1A2 (0.40) KDM4EMAPTNPSR1GLAGAA
SCHEMBL860644 0.71 KDM4E (0.36) KDM4EMAPTNPSR1RCE1GAA
SCHEMBL844521 0.71 KDM4E (0.36) KDM4EMAPTRCE1KMT2AALDH1A1
SCHEMBL5657000 0.70 CYP1A2 (0.49) KDM4EGLAGAARXFP1CYP1A2
SCHEMBL859206 0.69 PKM (0.39) KDM4EMAPTRCE1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2432776-B1 METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS UNIV LAVAL (CA) 2019-09-11 EP disclosed
US-9315521-B2 Pyrimidines as novel therapeutic agents UNIVERSITé LAVAL (CA) 2016-04-19 US disclosed
US-20150225423-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITé LAVAL (CA) 2015-08-13 US disclosed
US-9040538-B2 Pyrimidines as novel therapeutic agents UNIVERSITE LAVAL (CA) 2015-05-26 US disclosed
EP-2432776-A1 METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS Chlorion Pharma, Inc. (CA) 2012-03-28 EP disclosed
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS UNIVERSITE LAVAL (CA) 2010-11-25 US disclosed
WO-2010132999-A1 METHYL SULFANYL PYRMIDMES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS CHLORION PHARMA, INC. (CA) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298336-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS TYMS, P2RX2, TYMP KDM4E 3841/4885MAPT 385/4885NPSR1 1771/4885
US-20150225423-A1 PYRIMIDINES AS NOVEL THERAPEUTIC AGENTS TYMS, P2RX2, TYMP KDM4E 3841/4885MAPT 385/4885NPSR1 1771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.